US 8,999,657 B2 · Reagents, methods, and kits for the classification of cancer

Abstract

Reagents, methods, and kits for the classification of cancer that comprise or employ antibodies that bind specific regions of CD43. One method includes contacting tissue with an antibody capable of specifically binding the cytoplasmic tail of CD43, contacting the tissue with an antibody capable of specifically binding the extracellular domain of CD43, and resolving cellular localization of any binding to the tissue with the antibody capable of specifically binding the cytoplasmic tail of CD43 and the antibody capable of specifically binding the extracellular domain of CD43. The binding patterns of the antibodies can be used to characterize cancer as more aggressive or less aggressive and can distinguish small cell lung cancer from non-small cell lung cancer. The cancer may therefore be treated in accordance of the characterization.

Claims19

Dependent claims

A method of characterizing and/or treating cancerous tissue comprising:

contacting cancerous tissue with a first antibody in a format capable of resolving nuclear binding and cytoplasmic binding, wherein the first antibody is an antibody capable of specifically binding cytoplasmic tail of CD43 in the format;
contacting the tissue with a second antibody in the format capable of resolving nuclear binding and cytoplasmic binding, wherein the second antibody is an antibody capable of specifically binding extracellular domain of CD43;
and
resolving cellular localization of any binding to the tissue with the first antibody and the second antibody, wherein nuclear binding with the first antibody, a lack of cytoplasmic binding with the first antibody, a lack of nuclear binding with the second antibody, and a lack of cytoplasmic binding with the second antibody characterizes the tissue as being more aggressively cancerous than tissue not showing nuclear binding with the first antibody, a lack of cytoplasmic binding with the first antibody, a lack of nuclear binding with the second antibody, and a lack of cytoplasmic binding with the second antibody.

1 more element

A method of characterizing and/or treating cancerous tissue comprising:

contacting cancerous tissue with a first antibody in a format capable of resolving nuclear binding and cytoplasmic binding, wherein the first antibody is an antibody capable of specifically binding cytoplasmic tail of CD43 in the format;
contacting the tissue with a second antibody in the format capable of resolving nuclear binding and cytoplasmic binding, wherein the second antibody is an antibody capable of specifically binding extracellular domain of CD43;
and
resolving cellular localization of any binding to the tissue with the first antibody and the second antibody, wherein nuclear binding with the first antibody, a lack of cytoplasmic binding with the first antibody, a lack of nuclear binding with the second antibody, and a lack of cytoplasmic binding with the second antibody characterizes the tissue as being more aggressively cancerous than tissue not showing nuclear binding with the first antibody, a lack of cytoplasmic binding with the first antibody, a lack of nuclear binding with the second antibody, and a lack of cytoplasmic binding with the second antibody,
wherein the tissue is selected from the group consisting of lung tissue and breast tissue.

2 more elements

Dependencies are inferred from the claim text.

Reagents, methods, and kits for the classification of cancer

Life of this patent

Reagents, methods, and kits for the classification of cancer

Life of this patent

Abstract

Claims19